The Advanced Renal Cell Carcinoma market report also offers comprehensive insights into the Advanced Renal Cell Carcinoma market size, share, Advanced Renal Cell Carcinoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Advanced Renal Cell Carcinoma market size growth forward.
Some of the key highlights from the Advanced Renal Cell Carcinoma Market Insights Report:
-
Several key pharmaceutical companies, including CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics, and others, are developing novel products to improve the Advanced Renal Cell Carcinoma treatment outlook.
-
In July 2024, the US Food and Drug Administration (FDA) granted Fast Track designation to ADI-270, a novel drug for treating patients with metastatic or advanced clear cell renal cell carcinoma (RCC).
-
In July 2024, AVEO Oncology revealed that the TiNivo-2 Phase III clinical trial, which tested nivolumab combined with low-dose FOTIVDA® (tivozanib) in patients with advanced metastatic RCC who had previously undergone immune checkpoint inhibitor (ICI) treatment, did not meet its primary goal of improving progression-free survival (PFS).
-
June 2024, Adicet Bio announced that the FDA had cleared its investigational new drug (IND) application for ADI-270, enabling the company to launch a Phase I clinical trial for patients with relapsed/refractory RCC.
-
In June 2024, Telix Pharmaceuticals completed submitting a Biologics License Application (BLA) to the FDA for their radiodiagnostic PET agent, TLX250-CDx, which is used to image clear cell RCC (ccRCC).
-
In June 2024, the FDA approved Adicet Bio’s IND application, allowing the start of a Phase I trial for ADI-270 in patients with relapsed or refractory RCC (r/r RCC).
-
According to DelveInsight, the market for advanced renal cell carcinoma (RCC) is projected to experience steady growth at a solid compound annual growth rate (CAGR) by 2034.
-
Renal cell carcinoma is the most prevalent form of kidney cancer, representing about 90% of all kidney cancer cases. It ranks among the top ten most common cancers globally. The five-year survival rate for patients with advanced RCC is approximately 11-12%. RCC predominantly affects individuals over the age of 50 and is more common in men. Risk factors for RCC include smoking, obesity, high blood pressure, and a family history of conditions like von Hippel–Lindau disease.
-
The diagnosis and treatment of localized and metastatic RCC have significantly advanced in recent years. The use of abdominal CT scans or MRIs has led to an increased detection of asymptomatic lesions, contributing to a rise in diagnosed cases. Metastasis, where cancer cells spread from the kidneys, can occur in various areas of the body, including nearby lymph nodes, the renal vein, the vena cava, the other kidney, and the adrenal glands.
-
The treatment landscape for advanced RCC has been revolutionized with the introduction of immune checkpoint inhibitors and targeted therapies. These therapies, whether used alone or in combination, have significantly expanded the treatment options and improved survival rates for patients. By leveraging a deeper understanding of the molecular and genetic aspects of RCC, targeted therapies have proven to be powerful tools that greatly enhance patient outcomes. This dual approach marks a crucial development in the management of RCC, offering improved efficacy and prognosis for those facing this challenging disease.
-
Regulatory agencies and leading pharmaceutical companies are actively working to improve the treatment options for advanced RCC. A significant milestone was reached in December 2023, when the FDA approved Merck’s WELIREG, highlighting ongoing efforts to expand therapeutic options for this difficult-to-treat condition.
-
The competitive environment for advanced RCC is fierce, with numerous established and emerging therapies competing for market share, especially with the growing prevalence of combination treatments involving immunotherapy and tyrosine kinase inhibitors.
-
Leading companies in the advanced RCC market, such as Exelixis, Bristol-Myers Squibb (BMS), AstraZeneca, and HUTCHMED, are pushing forward with the development of new treatments for advanced renal cell carcinoma, demonstrating a strong commitment within the pharmaceutical industry to innovate and improve patient care for this aggressive cancer.
-
There are various forms of RCC, with clear cell being the most common, affecting 75% of patients.
-
The total Advanced Renal Cell Carcinoma market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
-
As per DelveInsight analysis, the Advanced Renal Cell Carcinoma market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Advanced Renal Cell Carcinoma Market Landscape
Advanced Renal Cell Carcinoma Overview
Renal cell carcinoma (RCC) is the most common type of kidney cancer, arising in the small tubules that help filter waste and direct essential substances into the bloodstream. When RCC spreads to other parts of the body, it becomes metastatic renal cell carcinoma (mRCC), also known as stage IV. While the progression rate of mRCC varies, recent advancements in treatment have improved patient outcomes and quality of life.
Common symptoms of RCC include blood in the urine, back pain, weight loss, fatigue, fever, and high blood pressure. As the cancer advances, symptoms like pain, shortness of breath, and weakness may develop, depending on where the cancer spreads.
The management of advanced RCC has improved with new treatments, surgical options, and personalized therapies. For patients with localized metastasis, surgery or ablative therapies may delay the need for systemic treatments. For those not eligible for surgery, alternatives like cryoablation and radiotherapy are recommended. Targeted therapies, such as tyrosine kinase inhibitors (TKIs) and anti-VEGF antibodies, are widely used in treatment, offering effective options for advanced RCC patients.
Do you know the treatment paradigms for different countries? Download our Advanced Renal Cell Carcinoma Market Sample Report
Advanced Renal Cell Carcinoma Epidemiology Segmentation
DelveInsight’s Advanced Renal Cell Carcinoma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Advanced Renal Cell Carcinoma historical patient pools and forecasted Advanced Renal Cell Carcinoma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Advanced Renal Cell Carcinoma Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
-
Advanced Renal Cell Carcinoma Prevalence
-
Age-Specific Advanced Renal Cell Carcinoma Prevalence
-
Gender-Specific Advanced Renal Cell Carcinoma Prevalence
-
Diagnosed and Treatable Cases of Advanced Renal Cell Carcinoma
Visit for more @ Advanced Renal Cell Carcinoma Epidemiological Insights
Advanced Renal Cell Carcinoma Market Outlook
Leading companies in the advanced renal cell carcinoma (RCC) market, such as Exelixis, Bristol-Myers Squibb (BMS), AstraZeneca, and HUTCHMED, are actively advancing their key candidates through various stages of clinical development. Their efforts are focused on improving treatments for advanced RCC, and the market outlook is optimistic due to their commitment to innovation and expanding therapeutic options. As these therapies progress, they have the potential to significantly enhance patient outcomes and address unmet needs. The competitive landscape is expected to grow dynamically, driven by advancements in targeted therapies, immunotherapies, and combination treatments, with the goal of improving survival rates and quality of life for patients.
Advanced Renal Cell Carcinoma Marketed Drugs
-
KEYTRUDA (pembrolizumab): Merck
-
WELIREG (belzutifan): Merck
Advanced Renal Cell Carcinoma Emerging Drugs
-
Zanzalintinib (XL092) + Nivolumab: Exelixis/BMS
-
Savolitinib + Durvalumab: AstraZeneca/HUTCHMED
Advanced Renal Cell Carcinoma Key Companies
-
CoImmune, Merck & Dohme, Xynomic Pharmaceuticals, NiKang Therapeutics, and others
For more information, visit Advanced Renal Cell Carcinoma Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Advanced Renal Cell Carcinoma Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Advanced Renal Cell Carcinoma, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Advanced Renal Cell Carcinoma epidemiology in the 7MM
-
Advanced Renal Cell Carcinoma marketed and emerging therapies
-
Advanced Renal Cell Carcinoma companies
-
Advanced Renal Cell Carcinoma market drivers and barriers
Table of Contents:
1 Advanced Renal Cell Carcinoma Market Key Comprehensive Insights
2 Advanced Renal Cell Carcinoma Market Report Introduction
3 Competitive Intelligence Analysis for Advanced Renal Cell Carcinoma
4 Advanced Renal Cell Carcinoma Market Analysis Overview at a Glance
5 Executive Summary of Advanced Renal Cell Carcinoma
6 Advanced Renal Cell Carcinoma Epidemiology and Market Methodology
7 Advanced Renal Cell Carcinoma Epidemiology and Patient Population
8 Advanced Renal Cell Carcinoma Patient Journey
9 Advanced Renal Cell Carcinoma Treatment Algorithm, Advanced Renal Cell Carcinoma Current Treatment, and Medical Practices
10 Key Endpoints in Advanced Renal Cell Carcinoma Clinical Trials
11 Advanced Renal Cell Carcinoma Marketed Therapies
12 Advanced Renal Cell Carcinoma Emerging Therapies
13 Advanced Renal Cell Carcinoma: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Advanced Renal Cell Carcinoma
16 Advanced Renal Cell Carcinoma Market Key Opinion Leaders Reviews
18 Advanced Renal Cell Carcinoma Market Drivers
19 Advanced Renal Cell Carcinoma Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Advanced Renal Cell Carcinoma Epidemiology 2034
DelveInsight’s “Advanced Renal Cell Carcinoma – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Advanced Renal Cell Carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Advanced Renal Cell Carcinoma Pipeline 2024
“Advanced Renal Cell Carcinoma Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Advanced Renal Cell Carcinoma market. A detailed picture of the Advanced Renal Cell Carcinoma pipeline landscape is provided, which includes the disease overview and Advanced Renal Cell Carcinoma treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/